Cognition Therapeutics, Inc. is a clinical stage biotechnology company located in Pittsburgh,
Pennsylvania. Founded in 2007, the company uses proprietary biology and chemistry platforms
to discover novel drug targets and disease modifying therapies for disorders of the central
Location: Pittsburgh, PA
Position Summary: Reporting to the Director of Screening and Principal Scientist, the
Research Associate I or II will be a key contributor to a scientific research team discovering drugs to treat Alzheimer’s disease.
Responsibilities include assisting with maintaining the company’s tissue culture facility,
culturing and maintenance of primary neurons, and execution of compound screens according
to prescribed protocols. Statistical analysis of complex screening data, presentation of data to
company scientists and maintenance of quality control documentation is required. The
candidate will also assist in development of new assays and experiments, and participate in
general laboratory management, including equipment/supply ordering.
Education & Experience:
- Bachelor’s degree in biology or neurobiology required, Master’s degree preferred
- Experience with assay methodology such as enzymatic reactions, immunocytochemistry
- Technical expertise in compound screening, automated liquid handling systems and
standard detection technology (plate readers, imagers) preferred
- Excellent organizational, problem-solving and verbal/written communication skills
- Literacy in all MS Office products and facility in learning other specialized applications
- Demonstrated ability to work cooperatively in a fast-paced multidisciplinary team
Research Associate I: Some industry experience in drug discovery preferred (including internships).
Research Associate II: A minimum of 5 years industry experience in drug discovery required.
About Cognition Therapeutics
Cognition Therapeutics (CogRx) is a privately held biopharmaceutical company whose disease-relevant screening and novel chemistry platforms have produced a pipeline of disease modifying small molecule drug candidates which are being developed to treat Alzheimer’s disease and potentially other neurocognitive disorders. Cognition’s lead molecule, CT1812, is a proprietary first-in-class, orally available small molecule that is currently in clinical trials in patients with mild-to-moderate Alzheimer’s disease. This highly brain penetrant compound targets the sigma-2/PGRMC1 receptor complex, displacing toxic beta amyloid oligomers from their binding sites on brain cells and clearing them into the cerebrospinal fluid. CT1812 has been shown in multiple Alzheimer’s disease models to stop memory loss. Additional information about Cognition may be found online at http://www.cogrx.com.